Last reviewed · How we verify
Thrombolytic
At a glance
| Generic name | Thrombolytic |
|---|---|
| Also known as | intravenous thrombolysis |
| Sponsor | Faculty Hospital Kralovske Vinohrady |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure (NA)
- Normal Saline Infusion After Intravenous Thrombolysis in Stroke (PHASE3)
- Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism (PHASE4)
- Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorrhage (PHASE3)
- Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients (PHASE4)
- Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO) (PHASE3)
- Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours (PHASE4)
- Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thrombolytic CI brief — competitive landscape report
- Thrombolytic updates RSS · CI watch RSS
- Faculty Hospital Kralovske Vinohrady portfolio CI